UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063705
Receipt number R000072851
Scientific Title Study on the efficacy and safety of Forel H tomy for drug-resistant epilepsy
Date of disclosure of the study information 2026/11/20
Last modified on 2026/11/20 09:48:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of the benefits and risks of using heat to treat a small area of the brain in people with epilepsy that does not respond to medicines

Acronym

Forel-H-tomy for Epilepsy

Scientific Title

Study on the efficacy and safety of Forel H tomy for drug-resistant epilepsy

Scientific Title:Acronym

Forel-H-tomy for Drug-Resistant Epilepsy

Region

Japan


Condition

Condition

Drug-resistant epilepsy

Classification by specialty

Neurosurgery Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of radiofrequency thermocoagulation of the field of Forel (Forel-H-tomy) for drug-resistant epilepsy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Seizure freedom rate at 12 months after surgery.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Participants undergo one session of stereotactic radiofrequency thermocoagulation of the field of Forel (Forel-H-tomy). A stereotactic frame is applied under local anesthesia, and the target is identified using MRI and CT. A lesioning electrode is inserted, and thermocoagulation is performed at 70 degrees for 40 seconds. The procedure takes approximately 30 minutes. Postoperative MRI is used to verify the lesion location and assess for hemorrhage.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Inpatients or outpatients at the Department of Neurosurgery, Tokyo Women's Medical University, with drug-resistant epilepsy diagnosed by an epilepsy specialist.
2. Failure to achieve at least 1 year of seizure control despite at least 2 years of treatment with adequate doses of two to three or more appropriate antiseizure medications, used as monotherapy or in combination, with seizures interfering with daily life.
3. Seizure onset clearly localized to one cerebral hemisphere based on clinical findings, electroencephalography, and neuroimaging.
4. Voluntary written informed consent provided by the participant after receiving an explanation of the study.

Key exclusion criteria

1. Current antiplatelet or anticoagulant treatment that cannot be interrupted.
2. Contraindication to MRI.
3. Pregnancy or breastfeeding.
4. Symptomatic hypotension or systolic blood pressure below 85 mmHg.
5. Deemed unsuitable for participation by the principal investigator.

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Shiro
Middle name
Last name Horisawa

Organization

Tokyo Women's Medical University

Division name

Department of Neurosurgery

Zip code

162-8666

Address

8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan

TEL

03-3353-8111

Email

neurosurgery0222@gmail.com


Public contact

Name of contact person

1st name Shiro
Middle name
Last name Horisawa

Organization

Tokyo Women's Medical University

Division name

Department of Neurosurgery

Zip code

1580086

Address

8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan

TEL

03-3353-8111

Homepage URL


Email

neurosurgery0222@gmail.com


Sponsor or person

Institute

Tokyo Women's Medical University

Institute

Department

Personal name



Funding Source

Organization

Department of Neurosurgery

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Review Committee, Tokyo Women's Medical University

Address

8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan

Tel

03-3353-8111

Email

rinri.bm@twmu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 20 Day


Related information

URL releasing protocol

Not publicly available

Publication of results

Partially published


Result

URL related to results and publications

https://doi.org/10.1002/epi4.12826

Number of participants that the trial has enrolled

6

Results

Six participants underwent unilateral Forel-H-tomy. At 12 months, 2/6 (33.3%) were seizure-free (Engel I), 2/6 had a seizure reduction of at least 50% (Engel III), and 2/6 were Engel IV. Persistent mild neurological adverse events occurred in 3/6. One participant was previously published as a case report.

Results date posted

2026 Year 11 Month 20 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Six participants with drug-resistant epilepsy were enrolled: four men and two women. Mean age at surgery was 65 years. All had focal to bilateral tonic-clonic seizures. Etiologies included intracerebral hemorrhage, ulegyria, hippocampal sclerosis, and acute subdural hematoma.

Participant flow

All six prospectively enrolled participants underwent unilateral Forel-H-tomy and were included in the clinical outcome analysis at 12 months.

Adverse events

At 12 months, three participants had persistent mild neurological adverse events: hypophonia in two and reduced manual dexterity in one. No life-threatening or fatal adverse events occurred.

Outcome measures

At 12 months, the seizure freedom rate was 2/6 (33.3%). Two additional participants (2/6, 33.3%) had a seizure reduction of at least 50%. Engel outcomes were class I in two, class III in two, and class IV in two. Persistent mild neurological adverse events were present in 3/6 participants (50.0%) at 12 months.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 04 Month 19 Day

Date of IRB

2021 Year 04 Month 20 Day

Anticipated trial start date

2021 Year 06 Month 28 Day

Last follow-up date

2023 Year 02 Month 01 Day

Date of closure to data entry

2023 Year 02 Month 01 Day

Date trial data considered complete

2023 Year 02 Month 01 Day

Date analysis concluded

2026 Year 11 Month 25 Day


Other

Other related information



Management information

Registered date

2026 Year 11 Month 20 Day

Last modified on

2026 Year 11 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072851